Efficacy of Fusion Imaging in Endovascular Revascularization of the Superficial Femoral Artery.


Journal

Annals of vascular surgery
ISSN: 1615-5947
Titre abrégé: Ann Vasc Surg
Pays: Netherlands
ID NLM: 8703941

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 30 05 2021
revised: 15 07 2021
accepted: 01 08 2021
pubmed: 18 10 2021
medline: 23 3 2022
entrez: 17 10 2021
Statut: ppublish

Résumé

The demand for endovascular revascularization (ER) to treat peripheral artery disease (PAD) has steadily increased. However, ER comes at the cost of increased contrast and radiation exposure, particularly in more complex cases. Fusion imaging is a new technology that may address these issues. The purpose of this study was to evaluate the efficacy of fusion imaging in ER of the superficial femoral artery (SFA). Patients with PAD undergoing ER of the SFA from February 2016 to July 2020 were retrospectively evaluated. A group of patients treated using fusion imaging was compared with a control group treated without fusion imaging. The primary end points were the contrast dose, fluoroscopy time, radiation dose, and operative time. A total of 51 patients (fusion group, n = 26; control group, n = 25) underwent ER during the study period. Significantly lower iodinated contrast doses were observed in the fusion than in the control group (56.1 ± 23.7 vs. 87.9 ± 44.9 mL; P = 0.003), as well as significantly shorter fluoroscopy times (21.2 ± 11.1 vs. 44.9 ± 31.4 min; P = 0.001), lower radiation exposure (29.9 ± 8.9 vs. 122.2 ± 223.1 mGy; P = 0.04), and shorter operative times (88.3 ± 32.1 vs. 126.1 ± 66.8 min; P = 0.013). The use of fusion imaging technology during ER of the SFA can significantly reduce the contrast dose, fluoroscopy time, radiation dose, and operative time.

Sections du résumé

BACKGROUND BACKGROUND
The demand for endovascular revascularization (ER) to treat peripheral artery disease (PAD) has steadily increased. However, ER comes at the cost of increased contrast and radiation exposure, particularly in more complex cases. Fusion imaging is a new technology that may address these issues. The purpose of this study was to evaluate the efficacy of fusion imaging in ER of the superficial femoral artery (SFA).
METHODS METHODS
Patients with PAD undergoing ER of the SFA from February 2016 to July 2020 were retrospectively evaluated. A group of patients treated using fusion imaging was compared with a control group treated without fusion imaging. The primary end points were the contrast dose, fluoroscopy time, radiation dose, and operative time.
RESULTS RESULTS
A total of 51 patients (fusion group, n = 26; control group, n = 25) underwent ER during the study period. Significantly lower iodinated contrast doses were observed in the fusion than in the control group (56.1 ± 23.7 vs. 87.9 ± 44.9 mL; P = 0.003), as well as significantly shorter fluoroscopy times (21.2 ± 11.1 vs. 44.9 ± 31.4 min; P = 0.001), lower radiation exposure (29.9 ± 8.9 vs. 122.2 ± 223.1 mGy; P = 0.04), and shorter operative times (88.3 ± 32.1 vs. 126.1 ± 66.8 min; P = 0.013).
CONCLUSIONS CONCLUSIONS
The use of fusion imaging technology during ER of the SFA can significantly reduce the contrast dose, fluoroscopy time, radiation dose, and operative time.

Identifiants

pubmed: 34656727
pii: S0890-5096(21)00724-X
doi: 10.1016/j.avsg.2021.08.016
pii:
doi:

Substances chimiques

Contrast Media 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

206-212

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Makoto Haga (M)

Department of Cardiovascular Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan. Electronic address: makko420@gmail.com.

Kouhei Fujimura (K)

Department of Radiology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.

Shunya Shindo (S)

Center for Preventive Medicine, Yamanashi Kosei Hospital, Yamanashi, Japan.

Ayako Nishiyama (A)

Department of Cardiovascular Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.

Mitsuhiro Kimura (M)

Department of Cardiovascular Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.

Shinya Motohashi (S)

Department of Cardiovascular Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.

Hidenori Inoue (H)

Department of Cardiovascular Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.

Junetsu Akasaka (J)

Department of Cardiovascular Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH